Shawki O, Peters A, Abraham-Hebert S
Unit of Advanced Laparoscopic Surgery, Al Ebtesama Hospital, Heliopolis, Cairo, Egypt.
JSLS. 2002 Jan-Mar;6(1):23-7.
To compare the outcome and cost-effectiveness of various forms of preoperative endometrial preparation prior to hysteroscopic endometrial destruction for abnormal uterine bleeding.
This was a multicenter, prospective, comparative, randomized study conducted in a tertiary care hospital in Cairo, Egypt and 2 academic tertiary care teaching hospitals in the United States. One hundred thirty-one premenopausal women, who had completed childbearing, mean age of 45.7 years, with abnormal uterine bleeding refractory to medical management without histologic evidence of endometrial neoplasia were studied. The 131 patients were randomized for preoperative preparation for hysteroscopic endometrial destruction into 1 of 5 groups as follows: Group I, dilation and curettage (D & C) (39); Group II, gonadotropin-releasing hormone analogue (GnRHa) for 1 month (23); Group III, GnRHa for 3 months (26); Group IV, danazol for 3 months (26); and Group V, medroxyprogesterone acetate (MPA) 15 mg for 3 months (27). The choice of endometrial ablation or endometrial resection was left to the surgeon.
Improvement in bleeding patterns, amenorrhea, operative times, complications, and relative cost were the measured outcomes. The mean follow-up time was 1 year from the time of the procedure. Overall, in Group I, 39/39 (100%) improved and 7/39 (18.0%) experienced amenorrhea; in Group II, 21/23 (91.3%) improved and 9/23 (39.1%) experienced amenorrhea; in Group III, 24/26 (92.3%) improved and 10/26 (38.5%) experienced amenorrhea; in Group IV, 24/26 (92.3%) improved and 9/26 (34.6%) experienced amenorrhea; and in Group V, 23/27 (85.1%) improved and 7/27 (25.9%) experienced amenorrhea.
Endometrial destruction whether by the ablation or resection technique, regardless of the type of surgical pretreatment is a safe and effective surgical approach for treating abnormal uterine bleeding. D & C or MPA appear to be the most cost-effective pretreatment regimens. MPA pretreatment may confer the added advantage of decreasing blood flow and allowing better hysteroscopic visualization than D & C pretreatment.
比较宫腔镜下子宫内膜破坏术治疗异常子宫出血前各种形式的术前子宫内膜准备的效果和成本效益。
这是一项多中心、前瞻性、比较性、随机研究,在埃及开罗的一家三级护理医院和美国的两家学术性三级护理教学医院进行。研究对象为131名已完成生育的绝经前妇女,平均年龄45.7岁,有异常子宫出血,药物治疗无效且无子宫内膜肿瘤组织学证据。131例患者被随机分为5组,进行宫腔镜下子宫内膜破坏术的术前准备,分组如下:第一组,刮宫术(D&C)(39例);第二组,促性腺激素释放激素类似物(GnRHa)治疗1个月(23例);第三组,GnRHa治疗3个月(26例);第四组,达那唑治疗3个月(26例);第五组,醋酸甲羟孕酮(MPA)15mg治疗3个月(27例)。子宫内膜消融或切除的选择由外科医生决定。
测量的结果包括出血模式的改善、闭经、手术时间、并发症和相对成本。从手术时起平均随访时间为1年。总体而言,第一组中,39/39(100%)症状改善,7/39(18.0%)出现闭经;第二组中,21/23(91.3%)症状改善,9/23(39.1%)出现闭经;第三组中,24/26(92.3%)症状改善,10/26(38.5%)出现闭经;第四组中,24/26(92.3%)症状改善,9/26(34.6%)出现闭经;第五组中,23/27(85.1%)症状改善,7/27(25.9%)出现闭经。
无论是采用消融还是切除技术进行子宫内膜破坏,无论手术预处理的类型如何,都是治疗异常子宫出血的一种安全有效的手术方法。刮宫术或MPA似乎是最具成本效益的预处理方案。MPA预处理可能具有比刮宫术预处理更大的优势,即减少血流并使宫腔镜视野更清晰。